Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;46(11):4418-4426.
doi: 10.1177/0300060518799612. Epub 2018 Sep 18.

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy

Jin Zhang  1 , Shenhe Jin  1 , Xiaojun Guo  2 , Wenbin Qian  3   4
Affiliations
Review

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy

Jin Zhang et al. J Int Med Res. 2018 Nov.

Abstract

The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma.

Keywords: B-cell lymphoma; CD47; SIRPα; combination strategy; immunoglobulin; immunotherapy.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30. doi: 10.3322/caac.21442. - PubMed
    1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613–626. doi: 10.1056/NEJMra0708875. - PubMed
    1. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2018; 15: 31–46. doi: 10.1038/nrclinonc. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377: 2531–2544. doi: 10.1056/NEJMoa1707447. - PMC - PubMed
    1. Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017; 102: 30–42. doi: 10.3324/haematol.2016.150656. - PMC - PubMed